These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35526696)

  • 1. The influence of poly(allylamine hydrochloride) hydrogel crosslinking density on its thermal and phosphate binding properties.
    Elsiddig R; O'Reilly NJ; Hudson SP; Owens E; Hughes H; O'Grady D; McLoughlin P
    Int J Pharm; 2022 Jun; 621():121806. PubMed ID: 35526696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
    Autissier V; Damment SJ; Henderson RA
    J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose-specific poly(allylamine) hydrogels--a reassessment.
    Fazal FM; Hansen DE
    Bioorg Med Chem Lett; 2007 Jan; 17(1):235-8. PubMed ID: 17035016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.
    Burke SK; Slatopolsky EA; Goldberg DI
    Nephrol Dial Transplant; 1997 Aug; 12(8):1640-4. PubMed ID: 9269642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endotoxin-binding affinity of sevelamer hydrochloride.
    Perianayagam MC; Jaber BL
    Am J Nephrol; 2008; 28(5):802-7. PubMed ID: 18506105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic and thermodynamic evaluation of phosphate ions binding onto sevelamer hydrochloride.
    Elsiddig R; Hughes H; Owens E; O' Reilly NJ; O'Grady D; McLoughlin P
    Int J Pharm; 2014 Oct; 474(1-2):25-32. PubMed ID: 25102115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography.
    Swearingen RA; Chen X; Petersen JS; Riley KS; Wang D; Zhorov E
    J Pharm Biomed Anal; 2002 Jun; 29(1-2):195-201. PubMed ID: 12062678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
    Chertow GM; Burke SK; Lazarus JM; Stenzel KH; Wombolt D; Goldberg D; Bonventre JV; Slatopolsky E
    Am J Kidney Dis; 1997 Jan; 29(1):66-71. PubMed ID: 9002531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats.
    Rosenbaum DP; Holmes-Farley SR; Mandeville WH; Pitruzzello M; Goldberg DI
    Nephrol Dial Transplant; 1997 May; 12(5):961-4. PubMed ID: 9175050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular modeling studies of the binding characteristics of phosphates to sevelamer hydrochloride--assessing a novel technique to reduce phosphates contamination.
    Parker R; Odukale AA; Fisher D; Batich C; Ross E; Edwards J
    Int J Environ Res Public Health; 2006 Jun; 3(2):202-8. PubMed ID: 16823094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phosphate binding assay for sevelamer hydrochloride by ion chromatography.
    Mazzeo JR; Peters RM; Hanus MR; Chen X; Norton KA
    J Pharm Biomed Anal; 1999 May; 19(6):911-5. PubMed ID: 10698557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient acid exposure increases sevelamer HCl phosphate binding.
    Ross EA; Scott WE; Odukale AA; Alba NA; Batich CD
    J Pharm Sci; 2007 Aug; 96(8):2154-60. PubMed ID: 17506513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.
    Goldsmith DR; Scott LJ; Cvetković RS; Plosker GL
    Drugs; 2008; 68(1):85-104. PubMed ID: 18081374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
    Taniguchi K; Kakuta H
    Eur J Pharmacol; 2015 Nov; 766():129-34. PubMed ID: 26452517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.
    Brewster UC; Ciampi MA; Abu-Alfa AK; Reilly RF
    Nephrology (Carlton); 2006 Apr; 11(2):142-6. PubMed ID: 16669977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel dosage forms and regimens for sevelamer-based phosphate binders.
    Duggal A; Hanus M; Zhorov E; Dagher R; Plone MA; Goldberg J; Burke SK
    J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.
    Mahdavi H; Kuizon BD; Gales B; Wang HJ; Elashoff RM; Salusky IB
    Pediatr Nephrol; 2003 Dec; 18(12):1260-4. PubMed ID: 14586677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients.
    Chertow GM; Burke SK; Dillon MA; Slatopolsky E
    Nephrol Dial Transplant; 1999 Dec; 14(12):2907-14. PubMed ID: 10570096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.
    Nagano N; Miyata S; Obana S; Ozai M; Kobayashi N; Fukushima N; Burke SK; Wada M
    Nephrol Dial Transplant; 2001 Sep; 16(9):1870-8. PubMed ID: 11522872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder.
    Nagano N; Miyata S; Obana S; Eto N; Fukushima N; Burke SK; Wada M
    Nephron; 2001 Nov; 89(3):321-8. PubMed ID: 11598397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.